ClinicalTrials.gg
Drug

Velpatasvir clinical trials

Also written GS-5816.

studies test it
55
open now
1
in phase 3
15
first study started
2012

Counted the way a researcher would: Velpatasvir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses velpatasvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the velpatasvir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Jun 2016 · EPCLUSA · NDA 208341 (FDA, Drugs@FDA; in a combination)
European Union
6 Jul 2016 · Epclusa · EMEA/H/C/004210 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Velpatasvir
4
VEL
3

Development codes

GS-5816
7

In one entry with another drug

Given together, or one or the other

SOF/VEL
23
GS-7977/GS-5816
22
sofosbuvir/velpatasvir
10
GS-7977/GS-5816/GS-9857
4
Sofosbuvir/Velpatasvir/Voxilaprevir
3
Velpatasvir/Sofosbuvir
2

Studies by the year they started

55 studies that test it; most in 2015 (9)

Studies that test velpatasvir, by start year
YearStudies
20121
20135
20147
20159
20168
20177
20184
20196
20202
20211
20223
20231
20241

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
21
Phase 3
15
Phase 4
12
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 31 · Other 24

Gilead Sciences (31) · Kirby Institute (3) · Catherine Anne Chappell (1) · Amit D Tevar, MD (1) · Mary E. Keebler, MD (1) · Fernanda P Silveira, MD, MS (1) · Elizabeth Krans, MD (1) · Alexandria University (1)

Often tested with

Tested in the same studies.

Sofosbuvir (30) · Voxilaprevir (10) · Ribavirin (7) · Sofosbuvir velpatasvir voxilaprevir drug combination (2) · Ledipasvir, sofosbuvir drug combination (2) · Ledipasvir (1) · Glecaprevir and pibrentasvir (1) · Interferons (1)

Studies

Open first, then newest update. How each study uses velpatasvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 55

See all 55 studies that test velpatasvir →

Given beside what is tested · 9 — velpatasvir is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with velpatasvir

Codes

What other systems call velpatasvir · ClinicalTrials.gg INT000378

  • MeSH (NLM) C000604171velpatasvirConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) KCU0C7RS7ZVELPATASVIRConfirmed FDA, NLM, Wikidata
  • RxNorm 1799206Confirmed FDA, Wikidata
  • Wikidata Q25018296velpatasvirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152851VelpatasvirOne source FDA
  • DrugBank DB11613One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.